



## ASX ANNOUNCEMENT

### Investor Communication Channels

**MELBOURNE, Australia (11 November 2021):** Lumos Diagnostics (ASX: LDX) is pleased to note the following communication which has been distributed to shareholders today, which highlights various online communication channels available to shareholders.

This announcement has been approved by the Lumos Disclosure Committee.

###

#### About Lumos Diagnostics

*Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.*

*For more information about Lumos Diagnostics and the CoviDx SARS-CoV-2 rapid antigen test, visit [lumosdiagnostics.com](http://lumosdiagnostics.com).*

#### Forward-Looking Statements

*This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.*

#### Media Contacts (U.S. and Global):

Jennifer Christiansen – Lumos Diagnostics  
jennifer.christiansen@lumosdiagnostics.com  
+1 920 784 3153

#### Media Contact (Australia):

Haley Chartres – H<sup>^</sup>CK  
haley@hck.digital  
+61 423 139 163



**Investor Contact:**

Matthijs Smith

[ir@lumosdiagnostics.com](mailto:ir@lumosdiagnostics.com)

+61 411 137 080

+61 3 9087 1598

**Company Registered Office:**

Lumos Diagnostics Holdings Ltd

Level 4, 100 Albert Rd

South Melbourne, VIC 3205

+61 3 9087 1598



**11 November 2021**

Dear Shareholder:

**Lumos Diagnostics Holdings Limited – Investor Communications**

As a company, Lumos Diagnostics is committed to communicating effectively with its shareholders and other stakeholders on an ongoing basis (as outlined in the Company's [Communications Policy](#)).

In order to deliver information directly to shareholders and broader stakeholders, Lumos has established a series of online communications channels, which the Company encourages shareholders to utilise to streamline their access to company information and updates.

The Lumos Investor News subscription portal has been developed for shareholders to receive company updates and news directly from the Company. You can access this by subscribing at <https://lumosdiagnostics.com/subscribe-to-investor-news/>.

In addition, shareholders can follow the Company's progress on our social media channel:

- LinkedIn – <https://www.linkedin.com/company/lumos-diagnostics/>
- Twitter – <https://twitter.com/LumosDX>; [@LumosDX](#)

To ensure consistency with our obligations under the ASX listing rules our corporate updates and information are reviewed on an ongoing basis by the Lumos Continuous Disclosure Committee under our Continuous Disclosure Policy.

We support electronic communications with all shareholders and note that shareholders can also update their communications preferences with the Company's Share Registry, Computershare via <https://www.computershare.com/au>.

Other methods of communication with shareholders and stakeholders include:

**Email:**

Shareholders can email the company directly at [ir@lumosdiagnostics.com](mailto:ir@lumosdiagnostics.com)

**General Meetings:**

The Company recently held its Annual General Meeting on 28 October 2021. A copy of the presentation given at the meeting can be accessed on our website and via ASX. [LDX share price and company information for ASX:LDX](#)

**ASX Announcements:**

The Company's ASX announcements are accessible via: [LDX share price and company information for ASX:LDX](#)



**Company Website Investor Centre:**

The [Investor Section](#) of the Company's website ([Corporate Governance - Lumos Diagnostics](#)), serves as a key repository of all Company information, including:

- ASX Announcements
- Corporate Governance – Policies and Charters
- Annual Reports – current and prior years
- Investor Presentations
- Board and Executive profiles

We are committed to supporting all shareholders and stakeholders with access to information about our business and products/services and encourage you all to access company information via whichever channels are most effective for you.

Yours sincerely,

A handwritten signature in black ink, appearing to read "Melanie Leydin", written in a cursive style.

Melanie Leydin  
Company Secretary  
Lumos Diagnostics Holdings Limited